Targetable vulnerabilities to overcome drug resistance in poor outcome breast cancers – EMC2
Targetable vulnerabilities to overcome drug resistance in poor outcome breast cancers – EMC2
Targetable vulnerabilities to overcome drug resistance in poor outcome breast cancers – EMC2
Targetable vulnerabilities to overcome drug resistance in poor outcome breast cancers – EMC2

One of the greatest challenges in breast cancer treatment is the recognition that tumors are highly diverse. This variability between and within tumors gives rise to cancer cells that can spread from the primary tumor to distant sites in the body, a process called metastasis, which is the deadliest aspect of the disease. Based on recent research, medical oncology has focused on personalizing therapeutic approaches to the patient’s specific disease with the aim of improving outcomes. In breast cancer, this involves identifying cancer subtypes that are predicted to respond to standard of care chemotherapy as well as targeted therapies. As effective as they are, metastatic breast cancers are often refractory to these treatments from the beginning or they develop resistance to the therapy over time.

The team of Prof. Park, Dr. Pollak and Prof. Mader aims to develop a new understanding of cancer vulnerabilities integrating cutting edge technologies to a patient-centric research approach. Using this method, they have discovered two new therapeutic approaches and propose to integrate these and others to develop new strategies to target deadly treatment-resistant and metastatic breast cancers for which no treatment currently exists.

Principal Researchers

Rosalind and Morris Goodman Cancer Research Centre
Lady Davis Institute for Medical Research – Segal Cancer Center
Institute for Research in Immunology and Cancer (IRIC)

Co-applicants & Users

Lady Davis Institute for Medical Research - Jewish General Hospital of Montreal
Lady Davis Institute for Medical Research - Jewish General Hospital of Montreal
Lady Davis Institute for Medical Research - Jewish General Hospital of Montreal
Lady Davis Institute for Medical Research - Jewish General Hospital of Montreal
Research Center of the University of Montreal Hospital Center (CRCHUM)
University of Montreal
Summary
Principal Investigators
Morag Park
Michael Pollack
Sylvie Mader
Competition
EMC2
Status
Closed
Beginning
August 2018
Scheduled End
July 2021
Budget
1 500 000 $
Partners
Cancer Research Society
Genome Québec